Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Is There a Clinical Benefit to Switch Hydroxyurea (HU) Drug in Sickle Cell Disease (SCD)?

Frédéric Galactéros, MDPhD, Ersi Voskaridou, Anoosha Habibi, MD PhD, Giovanna Cannas, MD, Laure Joseph, MD, Gylna Loko, MD, Mariane De Montalembert, MD PhD, Narcisse Elenga, MD PhD, Malika Benkerrou, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140265

Published: 2020

Journal Articles

Sickle-Cell Disease Patients' Attitudes Towards Their Treatment with Hydroxycarbamide

Frédéric Galactéros, MD PhD, Ersi Voskaridou, Anoosha Habibi, Giovanna Cannas, MD, Laure Joseph, MD, Stephanie Ngo, MD, Nathalie Lemonne, Emmanuelle Bernit, MD, Justine Gellen-Dautremer, MD, Gylna Loko, MD

Blood (2019) 134 (Supplement_1): 1013.

https://doi.org/10.1182/blood-2019-125673

Published: 2019

Journal Articles

Predictive Factors for Survival in Sickle Cell Disease: A Cohort Study Using Etendard Data

Laurent Savale, MD PhD, Gylna Loko, MD, François Lionnet, Bernard Maitre, Anoosha Habibi, Jocelyn Inamo, Dora Bachir, MD, Françoise Driss, Vincent Audard, MDPhD, Etienne Audureau, Marc Humbert, Gerald Simonneau, Frédéric Galactéros, MDPhD, Florence Parent, Pablo Bartolucci, MD PhD

Blood (2018) 132 (Supplement 1): 7.

https://doi.org/10.1182/blood-2018-99-113767

Published: 2018

Journal Articles

Off-Label Prescription of Hydroxycarbamide (Hydroxyurea, HU) for Severe Anemia: Preliminary Results from European Non-Interventional, Multicentric, Prospective Escort-HU Study

Mariane De Montalembert, MD PhD, Gylna Loko, MD, Jerome Clouzeau, MD, Valentine Brousse, MD, Frederic Galacteros, MDPhD, Corinne Charneau, MD, Marie Belloy, MD, Malika Benkerrou, MD

Blood (2017) 130 (Supplement 1): 758.

https://doi.org/10.1182/blood.V130.Suppl_1.758.758

Published: 2017

Journal Articles

Management of Renal Dysfunctions in Escort-HU Study

Pablo Bartolucci, MD PhD, Gylna Loko, MD, Corinne Charneau, MD, Jean-Antoine Ribeil, MD, Nathalie Lemonne, MD, Stephan Lobitz, MD, Malika Benkerrou, MD, Frederic Galacteros, MDPhD

Blood (2017) 130 (Supplement 1): 3528.

https://doi.org/10.1182/blood.V130.Suppl_1.3528.3528

Published: 2017

NARROW

Is There a Clinical Benefit to Switch Hydroxyurea (HU) Drug in Sickle Cell Disease (SCD)?

Sickle-Cell Disease Patients' Attitudes Towards Their Treatment with Hydroxycarbamide

Predictive Factors for Survival in Sickle Cell Disease: A Cohort Study Using Etendard Data

Off-Label Prescription of Hydroxycarbamide (Hydroxyurea, HU) for Severe Anemia: Preliminary Results from European Non-Interventional, Multicentric, Prospective Escort-HU Study

Management of Renal Dysfunctions in Escort-HU Study

Email alerts

ASH Publications

American Society of Hematology

Is There a Clinical Benefit to Switch Hydroxyurea (HU) Drug in Sickle Cell Disease (SCD)?

Sickle-Cell Disease Patients' Attitudes Towards Their Treatment with Hydroxycarbamide

Predictive Factors for Survival in Sickle Cell Disease: A Cohort Study Using Etendard Data

Off-Label Prescription of Hydroxycarbamide (Hydroxyurea, HU) for Severe Anemia: Preliminary Results from European Non-Interventional, Multicentric, Prospective Escort-HU Study

Management of Renal Dysfunctions in Escort-HU Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only